Stock ATH ALTERITY THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Alterity Therapeutics Limited Stock

Equities

ATH

AU0000043945

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 02:10:37 2024-06-12 am EDT 		5-day change 1st Jan Change
0.004 AUD -20.00% Intraday chart for Alterity Therapeutics Limited -20.00% -42.86%
May. 08 Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review CI
May. 08 Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November MT

Financials

Sales 2024 * 2.58M 3.86M Sales 2025 * 3.77M 5.64M Capitalization 17.3M 25.84M
Net income 2024 * -12M -17.93M Net income 2025 * -11M -16.43M EV / Sales 2024 * 5.49 x
Net cash position 2024 * 3.11M 4.65M Net cash position 2025 * 6.62M 9.89M EV / Sales 2025 * 2.83 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.93%
More Fundamentals * Assessed data

Chart Alterity Therapeutics Limited

Dynamic Chart

Latest news about Alterity Therapeutics Limited

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review CI
Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November MT
Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases CI
ADRs End Lower, Purple Biotech Ltd. Declines 29% DJ
ADRs End Lower, Leju Holdings Ltd. Declines 72% DJ
ADRs End Higher, Lixiang Education Holding Co. Ltd. Climbs 69% DJ
ADRs Close Lower; VIA Optronics AG Declines 30% DJ
Top Midday Gainers MT
Alterity Therapeutics Receives AU$3.9 Million R&D Tax Refund MT
Genetic Technologies Appoints CFO MT
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 30, 2023 CI
Alterity Therapeutics Raises AU$3.3 Million for Clinical Trials; Shares Fall 20% MT
Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review CI
Alterity Therapeutics Advances Phase Two Multiple System Atrophy Trial Following Committee Recommendation MT
More news

Latest transcript on Alterity Therapeutics Limited

Logo Alterity Therapeutics Limited
Alterity Therapeutics Limited - Shareholder/Analyst Call
More transcripts

Analyst Recommendations on Alterity Therapeutics Limited

Ladenburg Thalmann Initiates Alterity Therapeutics at Buy With $2 Price Target MT
Goldman Sachs Adjusts Alterity Therapeutics' Price Target to $3 from $11, Keeps Neutral Rating MT
Australian Shares Fall After US Fed Signals Earlier-than-Expected Rate Hike MT
ALTERITY THERAPEUTICS : Benchmark Starts Alterity Therapeutics at Speculative Buy With $4 Price Target MT
More recommendations

Press releases Alterity Therapeutics Limited

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund AQ
Alterity Therapeutics : Receives a $3.9 million Research & Development Tax Incentive Refund PU
Alterity Therapeutics : Voting ahead of attending the Meeting - Form 6-K PU
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review AQ
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week AQ
More press releases

Quotes and Performance

1 day-20.00%
1 week-20.00%
Current month-20.00%
1 month-20.00%
6 months-42.86%
Current year-42.86%
More quotes

Highs and lows

1 week
0.00
Extreme 0.004
0.01
1 month
0.00
Extreme 0.004
0.01
Current year
0.00
Extreme 0.003
0.01
1 year
0.00
Extreme 0.003
0.01
3 years
0.00
Extreme 0.003
0.04
5 years
0.00
Extreme 0.003
0.41
10 years
0.00
Extreme 0.003
0.41
More quotes

Managers and Directors - Alterity Therapeutics Limited

Managers TitleAgeSince
David Stamler CEO
 Chief Executive Officer 63 17-04-30
Geoffrey Kempler FOU
 Founder 69 97-11-10
Phillip Hains DFI
 Director of Finance/CFO 64 14-04-30
Members of the board TitleAgeSince
Geoffrey Kempler FOU
 Founder 69 97-11-10
Peter Marks BRD
 Director/Board Member 68 05-07-28
Lawrence Gozlan BRD
 Director/Board Member 45 11-08-07
More insiders

Quotes

Date Price Change Volume
24-06-12 0.004 -20.00% 204 950 043
24-06-11 0.005 0.00% 1,260,089
24-06-07 0.005 +25.00% 2,185,168
24-06-06 0.004 0.00% 2,677,794
24-06-05 0.004 -20.00% 74,400

Delayed Quote Australian S.E., June 12, 2024 at 02:10 am EDT

More quotes

Company Profile

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Sector
Biotechnology & Medical Research
Calendar
2025-02-26 - Q2 2025 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ALTERITY THERAPEUTICS LIMITED Stock Alterity Therapeutics Limited
-42.86% 17.3M
MODERNA, INC. Stock Moderna, Inc.
+47.20% 56.87B
LONZA GROUP AG Stock Lonza Group AG
+37.43% 39.72B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-6.34% 39.27B
CELLTRION, INC. Stock Celltrion, Inc.
-6.90% 28.73B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.47% 26.21B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-16.55% 19.79B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.48% 12.28B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+27.77% 12.23B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.12B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ATH Stock